MX2015017961A - Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. - Google Patents
Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.Info
- Publication number
- MX2015017961A MX2015017961A MX2015017961A MX2015017961A MX2015017961A MX 2015017961 A MX2015017961 A MX 2015017961A MX 2015017961 A MX2015017961 A MX 2015017961A MX 2015017961 A MX2015017961 A MX 2015017961A MX 2015017961 A MX2015017961 A MX 2015017961A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- organic compounds
- pyrrole
- pharmaceutical compositions
- related organic
- Prior art date
Links
- LVQORWACYOGJPF-UHFFFAOYSA-N C(N)(O)=O.N1=CC=C2C1=CC=N2 Chemical compound C(N)(O)=O.N1=CC=C2C1=CC=N2 LVQORWACYOGJPF-UHFFFAOYSA-N 0.000 title abstract 2
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 101000929834 Homo sapiens Monoacylglycerol lipase ABHD6 Proteins 0.000 abstract 1
- 102100035912 Monoacylglycerol lipase ABHD6 Human genes 0.000 abstract 1
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 1
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- DDLIQEWTNHONBH-UHFFFAOYSA-N carbamic acid;1h-pyrrole Chemical class NC(O)=O.C=1C=CNC=1 DDLIQEWTNHONBH-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842543P | 2013-07-03 | 2013-07-03 | |
| PCT/US2014/045145 WO2015003002A1 (en) | 2013-07-03 | 2014-07-01 | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017961A true MX2015017961A (es) | 2016-10-14 |
Family
ID=52144176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017961A MX2015017961A (es) | 2013-07-03 | 2014-07-01 | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9828379B2 (enExample) |
| EP (1) | EP3016653A4 (enExample) |
| JP (1) | JP6647592B2 (enExample) |
| CN (1) | CN105517547A (enExample) |
| CA (1) | CA2917050A1 (enExample) |
| MX (1) | MX2015017961A (enExample) |
| WO (1) | WO2015003002A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2017021805A1 (en) * | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| WO2017143283A1 (en) | 2016-02-19 | 2017-08-24 | Abide Therapeutics, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| WO2018053447A1 (en) * | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018093950A1 (en) * | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| AU2017361257B2 (en) | 2016-11-16 | 2022-02-10 | H. Lundbeck A/S. | Crystalline forms of a MAGL inhibitor |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MX2019008626A (es) * | 2017-01-20 | 2019-09-19 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). |
| NZ756915A (en) | 2017-03-13 | 2023-03-31 | Lundbeck La Jolla Research Center Inc | Dual magl and faah inhibitors |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
| US11161856B2 (en) * | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| MX2020007318A (es) * | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| CN112088001A (zh) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | Magl抑制剂 |
| JP2021531287A (ja) * | 2018-07-19 | 2021-11-18 | ファイザー・インク | Ｍａｇｌ阻害剤としての複素環式スピロ化合物 |
| CA3155260A1 (en) * | 2019-09-26 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods for reducing rewarding effects of morphine without affecting its analgesic effects |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| JP7525058B2 (ja) * | 2021-04-01 | 2024-07-30 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニスト |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100326D0 (sv) * | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| CA2716863A1 (en) * | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| DK3093291T3 (da) * | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| WO2011109277A1 (en) * | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| EP2444084A1 (en) * | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
-
2014
- 2014-07-01 CA CA2917050A patent/CA2917050A1/en not_active Abandoned
- 2014-07-01 WO PCT/US2014/045145 patent/WO2015003002A1/en not_active Ceased
- 2014-07-01 JP JP2016524330A patent/JP6647592B2/ja not_active Expired - Fee Related
- 2014-07-01 US US14/902,324 patent/US9828379B2/en not_active Expired - Fee Related
- 2014-07-01 MX MX2015017961A patent/MX2015017961A/es unknown
- 2014-07-01 EP EP14820480.3A patent/EP3016653A4/en not_active Withdrawn
- 2014-07-01 CN CN201480048531.6A patent/CN105517547A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016525092A (ja) | 2016-08-22 |
| US20160137649A1 (en) | 2016-05-19 |
| JP6647592B2 (ja) | 2020-02-14 |
| WO2015003002A1 (en) | 2015-01-08 |
| EP3016653A1 (en) | 2016-05-11 |
| CA2917050A1 (en) | 2015-01-08 |
| CN105517547A (zh) | 2016-04-20 |
| US9828379B2 (en) | 2017-11-28 |
| EP3016653A4 (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015017961A (es) | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| IN2012DN06720A (enExample) | ||
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| EA201391644A1 (ru) | Частично насыщенные трициклические соединения и способы их получения и применения | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| MX380147B (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida. | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| IN2015DN00376A (enExample) | ||
| EA201991073A1 (ru) | Ингибиторы magl | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201991074A1 (ru) | Ингибиторы magl | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| WO2013040227A3 (en) | Therapeutic compounds |